Investigating a brain circuit linked to lack of motivation in a genetic mouse model of schizophrenia

A novel circuit underlying amotivation in a mouse model of 22q11DS

NIH-funded research University of Tennessee Health Sci Ctr · NIH-11248091

This study is looking at how certain brain pathways might affect motivation in people with schizophrenia, using mice to help find new ways to improve motivation for those who struggle with it.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Tennessee Health Sci Ctr NIH-funded
Lab location1 site (Memphis, United States)
Project IDNIH-11248091 on NIH RePORTER

What this research studies

This research focuses on understanding a specific brain circuit that contributes to amotivation, a significant negative symptom of schizophrenia, using a mouse model of 22q11 deletion syndrome. The study aims to explore how disruptions in the thalamostriatal pathway and cholinergic signaling affect motivation. By examining these mechanisms, the researchers hope to identify potential new treatment options for individuals experiencing amotivation. The findings could lead to a better understanding of the underlying biology of this symptom and its impact on public health.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with 22q11 deletion syndrome or schizophrenia who experience significant motivational deficits.

Not a fit: Patients without a diagnosis of schizophrenia or 22q11 deletion syndrome may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatment strategies for improving motivation in individuals with schizophrenia.

How similar studies have performed: While the specific approach of targeting the thalamostriatal pathway in the context of amotivation is novel, similar studies have shown promise in understanding and treating other symptoms of schizophrenia.

Where this research is happening

Memphis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions 22q11 Chromosomal Microdeletion Syndrome22q11 Deletion Syndrome22q11.2 deletion syndromeaddictive disorderAutosomal dominant Opitz G/BBB syndrome
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.